MacArtney France has delivered a portable multi-beam echosounder hydrographic system, designed for small vessels, to the French government organisation, Collectivité de Corse, in Corsica.The Collectivité de Corse, a government organisation, represents the interests of the community of Corsica – a Mediterranean island off the south coast of France.With 1000 km of coastline, the island attracts many tourists and cruise ships creating the need for an MBES hydrographic system.The purpose of the MBES hydrographic system is to ensure visiting vessels can securely navigate the harbours of the island, monitor the seabed to control the quality of dredging, identify obstructions on the sea floor and verify underwater installations.MacArtney France worked with Kongsberg, Valeport and SBG Systems on this project to fulfill the project specific needs and supply an adaptable MBES hydrographic system that meets the standards set down by the International Hydrographic Organisation (IHO).This new bathymetric system from MacArtney France will reduce survey time, increase accuracy, expand survey area reach and ensure a comprehensive hydrographic survey system.
Sharing is caring! Tweet Share HealthLifestyle Drug firms cut vaccine prices to the developing world by: – June 6, 2011 Share 30 Views no discussions Share The vaccines will be sold at a price that covers the drugmakers’ costsSeveral major drugs companies have announced big cuts to the amounts they charge for their vaccines in the developing world.GlaxoSmithKline (GSK), Merck, Johnson & Johnson and Sanofi-Aventis have agreed to cut prices through the international vaccine alliance Gavi.GSK said it would cut the price of its vaccine for rotavirus by 67% to $2.50 (£1.50) a dose in poor countries.Rotavirus-related diarrhoea kills more than 500,000 children a year.The vaccine will be subsidised by higher prices being charged in richer countries.The rotavirus vaccine, for example, would cost about $50 in the US.‘Helped out’“What we need is a return to invest in the next generation of new vaccines and drugs and that has to come from the profits of the medicines or the vaccines,” Andrew Witty, chief executive of GSK told the BBC.“But it’s obvious that if you’re in Kenya or a slum in Malawi or somewhere like that there is no capacity for those people to contribute to it, so they have to be helped out by the contribution from the middle and the richer (countries).”Gavi is a partnership representing public and private sector organisations that helps to fund mass vaccination programmes in developing countries.It is committed to funding the introduction of rotavirus vaccinations in 40% of the poorest countries by 2015, but it faced a $3.7bn funding shortfall and so has been appealing for price cuts and donations.It will be holding a pledging conference in London on 13 June.Anti-poverty campaigners welcomed the move but also called on world leaders to act.“The pricing commitments announced today help drive momentum, but Gavi’s ambition to save four million lives in the next five years is only achievable if the international donor community steps up to the plate on 13 June,” said Jamie Drummond, executive director of campaign group ONE.Malaria vaccineMerck has said it will provide its own rotavirus vaccine for $5 a dose, coming down to $3.50 once more than 30 million doses have been sold.The price Gavi pays for pentavalent vaccines, which protect against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type B will be cut by two Indian firms, Serum Institute and Panacea Biotec.GSK also said it was very close to developing the world’s first malaria vaccine, which is unusual because there is no market for it in the West.That means there is no opportunity for patients in richer countries to subsidise those in poorer countries.As a result, GSK said that if the vaccine comes to market it would be sold at a price that provides a small return of 5%, which would be used to fund the next generation of malaria treatments.Save the Children called on other companies to replicate the “landmark move” which it said could prevent hundreds of thousands of “needless deaths”.“It’s important that Gavi now uses this to spur other vaccine producers to reduce prices and work to foster greater competition amongst producers to drive prices down even further and help even more children,” said chief executive Justin Forsyth.BBC News
Former Chelsea midfielder, John Obi Mikel, has left the door open for a potential move to the Egyptian Premier League in the future. Mikel The 33-year-old is a free agent after ending his contract with Turkish Super Lig club Trabzonspor by mutual agreement in March. Mikel quit the Black Sea Storm after expressing his fears over playing football amid the coronavirus pandemic. He was recently linked with a move to Brazilian side Botafogo who showed interest to sign him but the ex-Tianjin Teda captain claimed he was yet to make a final decision. During a chat with Egyptian media outfit OnTime Sports, the two-time English Premier League winner was quizzed about a potential move to the Egyptian top-flight. “Playing in the Egyptian Premier League? Why not?” said Mikel as reported by Kingfut.Advertisement “I am a professional footballer and everything is possible. I never ruled anything out. “My goal is to continue playing football, and I hope I will have the opportunity, I do not reject any offers made to me, but rather study them well until I make the right decision.” Mikel left Chelsea after more than 10 seasons at Stamford Bridge. There, he made 374 appearances and won eight major domestic honours and two European trophies. He returned to English football on a short-term deal at Middlesbrough, after a spell at Chinese top-flight outfit Tianjin Teda. read also:Iwobi: How Mikel influenced my Super Eagles career Having represented Nigeria at U17 and U20 level, he made his senior national team debut against Libya on August 17, 2005. Mikel went ahead to feature in two Fifa World Cup tournaments and four Africa Cup of Nations finals, where he won the title in 2013 and bronze medals in 2006, 2010 and 2019. FacebookTwitterWhatsAppEmail分享 Loading…
Share Julie Harrington takes the reins as BHA CEO August 11, 2020 The British Horseracing Authority (BHA) has confirmed that Charlie Parker, the new President of the Racehorse Owners’ Association (ROA), will join the company Board of Directors.Parker will replace former ROA President, Nicholas Cooper, as one of the two member nominated directors appointed collectively by the ROA, Thoroughbred Breeders Association (TBA) and National Trainers Federation (NTF).He will begin a three-year term as BHA Director on 1 July, joining Luca Cumani who joined the BHA Board in October 2019.Commenting on the new position, Parker said:“I am delighted to be joining the board of the BHA on behalf of the Horsemen’s Group. We face huge challenges across our industry which must be tackled together if we are to ensure the sport we all love can recover from the current crisis and grow into a more robust model in the future.”The BHA Chair, Annamarie Phelps, added “Charlie will be a valuable addition to our team of Directors and I look forward to working alongside him, our colleagues nominated by racecourses, and the independent members of our Board.“I’d like to thank Nicholas for his contribution to the BHA Board in what has been a challenging period for racing.” Share Related Articles Submit StumbleUpon HBLB gives £3.2m boost to UK racing August 13, 2020 On-course bookmakers return to UK courses in two-week trial August 17, 2020